Baseline disease activity indicators with response after initiation of first-line TNFα inhibitors, mean values±SD.
| Score | At baseline | At 6 months | At 18 months | |||
| Incl | Excl | Incl | Excl | Incl | Excl | |
| VAS pain | 65±17 | 64±22 | 30±23 | 35±27 | 35±28 | 35±26 |
| VAS fatigue | 68±24 | 66±24 | 29±25 | 40±27 | 37±28 | 42±29 |
| VAS global | 71±21 | 66±24 | 31±23 | 36±29 | 37±29 | 39±27 |
| VAS physician | 57±16 | 53±18 | 28±18 | 21±19 | 25±21 | 22±17 |
| CRP | 11±11 | 12±20 | 5.1±6.4 | 5.2±6.5 | 3.1±2.5* | 6.1±9.6* |
| HAQ | 1.2±0.7 | 1.0±0.7 | 0.6±0.6 | 0.6±0.6 | 0.7±0.7 | 0.8±0.7 |
| SJC | 5.5±3.3* | 3.8±3.6* | 1.5±1.8 | 1.1±2.4 | 1.5±2.5 | 1.1±2.1 |
| TJC | 6.3±3.8 | 5.4±4.4 | 2.0±3.1 | 2.2±4.4 | 2.4±3.7 | 1.8±3.1 |
| DAPSA28 | 45±18 | 39±24 | 18±16 | 18±15 | 18±14 | 18±15 |
| DAS28-CRP | 4.6±0.8* | 4.2±0.9* | 2.8±1.1 | 2.7±1.1 | 2.7±1.2 | 2.7±1.1 |
*Denotes a p value of <0.05 by unpaired t-test on testing for the statistical difference between incl and excl groups (both columns designated *).
CRP, C reactive protein; DAPSA28, Disease Activity Score in Psoriatic Arthritis for 28 joints; DAS28-CRP, Disease Activity Score 28-joint count C reactive protein; HAQ, Health Assessment Questionnaire; SJC, swollen joint count; VAS, Visual Analogue Scale.